Please assess the completion status of the following clinical trial:

Trial Title: Trial of Plasma Exchange for Severe Crescentic IgA Nephropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Biopsy-proven within 3ws~2. Primary IgAN or Henoch-Schönlein Purpura nephritis of crescent \>50%(\>8 glomeruli)~3. Serum creatinine ≥ 200 μmol/l， rapidly deterioration of renal function~Exclusion Criteria:~1. \<14 or \>65 years old~2. With high Scr requiring dialysis for≥ 3w~3. Scr\>200μmol/L ≥1 yr before entry~4. Main of old crescent ; Fibrous crescent\>50%~5. Anti-glomerular basement membrane (GBM) or antineutrophil cytoplasmic antibody (ANCA) antibody positive~6. Women in gestational and lactational period~7. With diabetes or uncontrollable malignant hypertension or Thrombotic Microangiopathy~8. With Malignancy~9. Chronic active infection including HBV hepatitis C virus (HCV) HIV or active tuberculosis~10. Other autoimmune disease~11. A second clearly defined cause of renal failure~12. Contraindication of plasma exchange treatment or steroid pulse~13. Patients who are unlikely to comply with the study protocol in the view of the treating physician.

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- PE and methylprednisolone pulse (Type: EXPERIMENTAL): Plasma exchange(PE) and methylprednisolone pulse therapy: plasma exchange \>7 within 3ws, Volume: 60ml/kg/course; Replacement fluid: 5% albumin or fresh frozen plasma and methylprednisolone pulse therapy Basic treatment: Oral prednisone was tapered from 1 mg/kg/d for 6wks, then diminish 5mg/d every 10d, stop at the sixth month; cyclophosphamide 1.5 mg/kg/d for 3 months, 50mg /d at 3 months and stopped at 6 month.
- Methylprednisolone pulse (Type: ACTIVE_COMPARATOR): Methylprednisolone pulse alone: methylprednisolone 7-15mg/kg/d 3 times on consecutive or alternate days Basic treatment: Oral prednisone was tapered from 1 mg/kg/d for 6wks, then diminish 5mg/d every 10d, stop at the sixth month; cyclophosphamide 1.5 mg/kg/d for 3 months, 50mg /d at 3 months and stopped at 6 month.

Based on this trial design, predict the completion outcome and termination type (if applicable).